Clinical Scorecard: FDA Approves First Generic Versions of FARXIGA
At a Glance
| Category | Detail |
|---|---|
| Condition | Type 2 Diabetes Mellitus |
| Key Mechanisms | Sodium-glucose cotransporter 2 inhibitor that reduces glucose and sodium reabsorption in the kidneys. |
| Target Population | Adults with type 2 diabetes mellitus and established cardiovascular disease or multiple cardiovascular risk factors. |
| Care Setting | Outpatient |
Key Highlights
- First generic versions of FARXIGA (dapagliflozin) approved by FDA.
- Indicated for reducing hospitalization risk for heart failure and improving glycemic control.
- Contraindicated in patients with prior serious hypersensitivity to dapagliflozin.
- Common adverse events include genital infections, nasopharyngitis, and urinary tract infections.
- Healthcare providers should consult the Orange Book for approved products.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of type 2 diabetes mellitus typically in adults.
Management
- Use dapagliflozin as an adjunct to diet and exercise for glycemic control.
Monitoring & Follow-up
- Monitor for signs of diabetic ketoacidosis and volume depletion.
Risks
- Risk of diabetic ketoacidosis, particularly in type 1 diabetes patients.
Patient & Prescribing Data
Adults with type 2 diabetes and cardiovascular risk factors.
Prescribing information consistent with branded product, including contraindications and precautions.
Clinical Best Practices
- Review full prescribing information for safety and dosing guidance.
- Consult the Orange Book for therapeutic equivalence evaluations.
- Educate patients on potential adverse effects and signs of complications.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
